177 related articles for article (PubMed ID: 26861921)
21. Intranasal glucagon: a promising approach for treatment of severe hypoglycemia.
Pontiroli AE
J Diabetes Sci Technol; 2015 Jan; 9(1):38-43. PubMed ID: 25385946
[TBL] [Abstract][Full Text] [Related]
22. Role of Dual-Hormone Closed-Loop Delivery System in the Future.
Bally L; Thabit H; Hovorka R
Diabetes Technol Ther; 2016 Aug; 18(8):452-4. PubMed ID: 27500812
[No Abstract] [Full Text] [Related]
23. Comparison of Insulin Pump Therapy and Multiple Daily Injections Insulin Regimen in Patients with Type 1 Diabetes During Ramadan Fasting.
Alamoudi R; Alsubaiee M; Alqarni A; Saleh Y; Aljaser S; Salam A; Eledrisi M
Diabetes Technol Ther; 2017 Jun; 19(6):349-354. PubMed ID: 28296467
[TBL] [Abstract][Full Text] [Related]
24. Postprandial glycemic excursions with the use of a closed-loop platform in subjects with type 1 diabetes: a pilot study.
van Bon AC; Hermanides J; Koops R; Hoekstra JB; DeVries JH
J Diabetes Sci Technol; 2010 Jul; 4(4):923-8. PubMed ID: 20663458
[TBL] [Abstract][Full Text] [Related]
25. Low-Carbohydrate Diet Impairs the Effect of Glucagon in the Treatment of Insulin-Induced Mild Hypoglycemia: A Randomized Crossover Study.
Ranjan A; Schmidt S; Damm-Frydenberg C; Steineck I; Clausen TR; Holst JJ; Madsbad S; Nørgaard K
Diabetes Care; 2017 Jan; 40(1):132-135. PubMed ID: 27797928
[TBL] [Abstract][Full Text] [Related]
26. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial.
El-Khatib FH; Balliro C; Hillard MA; Magyar KL; Ekhlaspour L; Sinha M; Mondesir D; Esmaeili A; Hartigan C; Thompson MJ; Malkani S; Lock JP; Harlan DM; Clinton P; Frank E; Wilson DM; DeSalvo D; Norlander L; Ly T; Buckingham BA; Diner J; Dezube M; Young LA; Goley A; Kirkman MS; Buse JB; Zheng H; Selagamsetty RR; Damiano ER; Russell SJ
Lancet; 2017 Jan; 389(10067):369-380. PubMed ID: 28007348
[TBL] [Abstract][Full Text] [Related]
27. Effect of continuous subcutaneous insulin infusion with lispro on hepatic responsiveness to glucagon in type 1 diabetes.
Launay B; Zinman B; Tildesley HD; Strack T; Chiasson JL
Diabetes Care; 1998 Oct; 21(10):1627-31. PubMed ID: 9773721
[TBL] [Abstract][Full Text] [Related]
28. The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes.
Rodriguez LM; Mason KJ; Haymond MW; Heptulla RA
Pediatr Res; 2007 Dec; 62(6):746-9. PubMed ID: 17957149
[TBL] [Abstract][Full Text] [Related]
29. Experiences of continuous subcutaneous insulin infusion in pregnant women with type 1 diabetes during delivery from four Italian centers: a retrospective observational study.
Fresa R; Visalli N; Di Blasi V; Cavallaro V; Ansaldi E; Trifoglio O; Abbruzzese S; Bongiovanni M; Agrusta M; Napoli A
Diabetes Technol Ther; 2013 Apr; 15(4):328-34. PubMed ID: 23537417
[TBL] [Abstract][Full Text] [Related]
30. Intranasal glucagon as remedy for hypoglycemia. Studies in healthy subjects and type I diabetic patients.
Pontiroli AE; Calderara A; Pajetta E; Alberetto M; Pozza G
Diabetes Care; 1989 Oct; 12(9):604-8. PubMed ID: 2676430
[TBL] [Abstract][Full Text] [Related]
31. Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial.
Battelino T; Tehranchi R; Bailey T; Dovc K; Melgaard A; Yager Stone J; Woerner S; von dem Berge T; DiMeglio L; Danne T
Pediatr Diabetes; 2021 Aug; 22(5):734-741. PubMed ID: 33934456
[TBL] [Abstract][Full Text] [Related]
32. Safety, efficacy and glucose turnover of reduced prandial boluses during closed-loop therapy in adolescents with type 1 diabetes: a randomized clinical trial.
Elleri D; Biagioni M; Allen JM; Kumareswaran K; Leelarathna L; Caldwell K; Nodale M; Wilinska ME; Haidar A; Calhoun P; Kollman C; Jackson NC; Umpleby AM; Acerini CL; Dunger DB; Hovorka R
Diabetes Obes Metab; 2015 Dec; 17(12):1173-9. PubMed ID: 26257323
[TBL] [Abstract][Full Text] [Related]
33. Treatment of mild-to-moderate hypoglycemia in patients with type 1 diabetes treated with insulin pump therapy: are current recommendations effective?
Gingras V; Desjardins K; Smaoui MR; Savard V; Messier V; Haidar A; Legault L; Rabasa-Lhoret R
Acta Diabetol; 2018 Mar; 55(3):227-231. PubMed ID: 29224132
[TBL] [Abstract][Full Text] [Related]
34. In-Clinic Evaluation of the MiniMed 670G System "Suspend Before Low" Feature in Children with Type 1 Diabetes.
Wood MA; Shulman DI; Forlenza GP; Bode BW; Pinhas-Hamiel O; Buckingham BA; Kaiserman KB; Liljenquist DR; Bailey TS; Shin J; Huang S; Chen X; Cordero TL; Lee SW; Kaufman FR
Diabetes Technol Ther; 2018 Nov; 20(11):731-737. PubMed ID: 30299976
[TBL] [Abstract][Full Text] [Related]
35. Minimizing morbidity of hypoglycemia in diabetes: a review of mini-dose glucagon.
Chung ST; Haymond MW
J Diabetes Sci Technol; 2015 Jan; 9(1):44-51. PubMed ID: 25160667
[TBL] [Abstract][Full Text] [Related]
36. Intranasal glucagon treatment relieves hypoglycaemia in children with type 1 (insulin-dependent) diabetes mellitus.
Stenninger E; Aman J
Diabetologia; 1993 Oct; 36(10):931-5. PubMed ID: 8243872
[TBL] [Abstract][Full Text] [Related]
37. Successful administration of intranasal glucagon in the out-of-hospital environment.
Sibley T; Jacobsen R; Salomone J
Prehosp Emerg Care; 2013; 17(1):98-102. PubMed ID: 22971130
[TBL] [Abstract][Full Text] [Related]
38. "Let the Algorithm Do the Work": Reduction of Hypoglycemia Using Sensor-Augmented Pump Therapy with Predictive Insulin Suspension (SmartGuard) in Pediatric Type 1 Diabetes Patients.
Biester T; Kordonouri O; Holder M; Remus K; Kieninger-Baum D; Wadien T; Danne T
Diabetes Technol Ther; 2017 Mar; 19(3):173-182. PubMed ID: 28099035
[TBL] [Abstract][Full Text] [Related]
39. Quantification of the glycemic response to microdoses of subcutaneous glucagon at varying insulin levels.
El Youssef J; Castle JR; Bakhtiani PA; Haidar A; Branigan DL; Breen M; Ward WK
Diabetes Care; 2014 Nov; 37(11):3054-60. PubMed ID: 25139882
[TBL] [Abstract][Full Text] [Related]
40. Effect of Repeated Glucagon Doses on Hepatic Glycogen in Type 1 Diabetes: Implications for a Bihormonal Closed-Loop System.
Castle JR; El Youssef J; Bakhtiani PA; Cai Y; Stobbe JM; Branigan D; Ramsey K; Jacobs P; Reddy R; Woods M; Ward WK
Diabetes Care; 2015 Nov; 38(11):2115-9. PubMed ID: 26341131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
